|
|
Vol. 25.34 – 4 November, 2024
|
|
|
|
|
|
|
|
Scientists showed that Cas9-mediated double-strand breaks induced large deletions at varying frequencies in cancer cell lines, human embryonic stem cells, and human primary T cells, and that most deletions were produced by two repair pathways. [Nature Biomedical Engineering]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
The authors demonstrated that hiPSC-neural stem/progenitor cells adopted a radial glia-associated signature, sharing key epigenetic and transcriptional characteristics with human fetal neural stem cells while exhibiting divergent profiles from glioblastoma stem cells.
[Nature Communications]
|
|
|
|
|
|
Researchers identified a specific expanded pathogenic subset of PD-1+CD8+ T cells in the liver, exhibiting strong functional activity and cytotoxicity against target cells.
[Advanced Science]
|
|
|
|
|
|
Scientists integrated clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced T cells (CARpos). [Cell Reports Medicine]
|
|
|
|
|
|
Investigators reported significant transcriptomic signatures of Cas13bt3 expression in retinal cells and show all-in-one adeno-associated virus gene therapy with Cas13bt3 can effectively silence VEGFA mRNA in human retinal organoids and humanized VEGF transgenic mouse models.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
The authors evaluated the efficiency of Myc-pH-low insertion peptide (pHLIP) in inserting the artificial c-Myc-tag onto the plasma membrane of malignant cells and determined if this engraftment could convert it into a therapeutic target for CAR-T cells or monoclonal antibodies.
[Cancer Letters]
|
|
|
|
|
|
Utilizing publicly accessible genome-wide association study data, this investigation evaluated the impact of over 5000 exposure variables on susceptibility to immune-related adverse events using univariate Mendelian randomization.
[Cancer Immunology Immunotherapy]
|
|
|
|
|
|
Scientists examined neural stem cell changes via mRNA sequencing in an in vitro Transwell co-culture model. They then explored cell interaction mechanisms using proliferation assays, differentiation assays, and neuron complexity analysis.
[Scientific Reports]
|
|
|
|
|
|
30 male Wistar albino rats were divided into three groups: sham, priapism, and priapism + mesenchymal stem cell treatment. The experimental groups were also divided into 1 and 12 hour subgroups of ischemic priapism. [International Urology and Nephrology]
|
|
|
|
|
|
|
|
CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies.
[Jama-Journal of The American Medical Association]
|
|
|
|
|
|
Investigators delve into the effect of tumor-derived exosomes on the CAR-T cell function and discuss how inhibiting their secretion can enhance the efficacy of CAR-T cell therapy.
[Inflammation and Regeneration]
|
|
|
|
|
|
The authors address the challenges to cell-based therapies against HIV and discuss the recent advancements aimed at overcoming them. [Journal of Cellular Biochemistry]
|
|
|
|
|
|
|
|
Allogene Therapeutics, Inc. announced that the US FDA granted RMAT designation to ALLO-316 for the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma.
[Allogene Therapeutics, Inc. (GlobenewsWire)]
|
|
|
|
|
|
An FDA announcement last year led to classwide black boxed warnings on existing CAR-T products’ labels. Now FDA is reconsidering those serious safety warnings with plans to change them potentially, Dr. Peter Marks, said in an interview with Fierce Pharma.
[Fierce Pharma]
|
|
|
|
|
|
The PhD project, has been awarded 3.25 million SEK from the Swedish Foundation for Strategic Research (SSF), will explore how small RNA molecules can be used to activate specific genes. AstraZeneca is providing additional funding, ensuring that the entire PhD project is fully financed for four years. [University of Gothenburg]
|
|
|
|
|
|
|
|
December 3-5, 2024 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
Hackensack Meridian Health – CDI – Nutley, New Jersey, United States
|
|
|
|
|
|
|
Stanford University – Stanford, California, United States
|
|
|
|
|
|
|
University College London – London, England, United Kingdom
|
|
|
|
|
|
|
Norwich Bioscience Institutes – Norwich, England, United Kingdom
|
|
|
|
|
|